» Articles » PMID: 18579783

In Silico Activity Profiling Reveals the Mechanism of Action of Antimalarials Discovered in a High-throughput Screen

Abstract

The growing resistance to current first-line antimalarial drugs represents a major health challenge. To facilitate the discovery of new antimalarials, we have implemented an efficient and robust high-throughput cell-based screen (1,536-well format) based on proliferation of Plasmodium falciparum (Pf) in erythrocytes. From a screen of approximately 1.7 million compounds, we identified a diverse collection of approximately 6,000 small molecules comprised of >530 distinct scaffolds, all of which show potent antimalarial activity (<1.25 microM). Most known antimalarials were identified in this screen, thus validating our approach. In addition, we identified many novel chemical scaffolds, which likely act through both known and novel pathways. We further show that in some cases the mechanism of action of these antimalarials can be determined by in silico compound activity profiling. This method uses large datasets from unrelated cellular and biochemical screens and the guilt-by-association principle to predict which cellular pathway and/or protein target is being inhibited by select compounds. In addition, the screening method has the potential to provide the malaria community with many new starting points for the development of biological probes and drugs with novel antiparasitic activities.

Citing Articles

transcription factor AP2-06B is mutated at high frequency in Southeast Asia but does not associate with drug resistance.

Shi Q, Wang C, Yang W, Ma X, Tang J, Zhang J Front Cell Infect Microbiol. 2025; 14():1521152.

PMID: 39835275 PMC: 11744005. DOI: 10.3389/fcimb.2024.1521152.


Stereospecific Resistance to N2-Acyl Tetrahydro-β-carboline Antimalarials Is Mediated by a PfMDR1 Mutation That Confers Collateral Drug Sensitivity.

Bremers E, Butler J, Do Amaral L, Merino E, Almolhim H, Zhou B ACS Infect Dis. 2025; 11(2):529-542.

PMID: 39808111 PMC: 11828674. DOI: 10.1021/acsinfecdis.4c01001.


Systematic in vitro evolution in reveals key determinants of drug resistance.

Luth M, Godinez-Macias K, Chen D, Okombo J, Thathy V, Cheng X Science. 2024; 386(6725):eadk9893.

PMID: 39607932 PMC: 11809290. DOI: 10.1126/science.adk9893.


Global Health Priority Box─Proactive Pandemic Preparedness.

Adam A, Besson D, Bryant R, Rees S, Willis P, Burrows J ACS Infect Dis. 2024; 10(12):4030-4039.

PMID: 39488746 PMC: 11650653. DOI: 10.1021/acsinfecdis.4c00700.


An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.

Duffy S, Sleebs B, Avery V Antimicrob Agents Chemother. 2024; 68(10):e0074624.

PMID: 39264187 PMC: 11459970. DOI: 10.1128/aac.00746-24.


References
1.
Payne D, Gwynn M, Holmes D, Pompliano D . Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006; 6(1):29-40. DOI: 10.1038/nrd2201. View

2.
Brinckerhoff C, Lubin M . Prolonged inhibition of protein and glycoprotein synthesis in tumor cells treated with muconomycin A. J Natl Cancer Inst. 1977; 58(3):605-9. DOI: 10.1093/jnci/58.3.605. View

3.
Chanda S, Caldwell J . Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today. 2003; 8(4):168-74. DOI: 10.1016/s1359-6446(02)02595-3. View

4.
Zhou Y, Zhou B, Chen K, Yan S, King F, Jiang S . Large-scale annotation of small-molecule libraries using public databases. J Chem Inf Model. 2007; 47(4):1386-94. DOI: 10.1021/ci700092v. View

5.
Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View